

HALF-YEAR REPORT ON THE LIQUIDITY CONTRACT WITH THE BROKERAGE FIRM KEPLER CHEUVREUX

Paris, France, January 17, 2024 – 06:00 pm CET – ACTICOR BIOTECH (ISIN: FR00140050J5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.

Under the liquidity contract entered into between ACTICOR BIOTECH and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2023:

- 65,122 shares
- € 299,098.61
- Number of executions on buy side on semester: 340
- Number of executions on sell side on semester: 227
- Traded volume on buy side on semester: 39,590 shares for € 173,764.12
- Traded volume on sell side on semester: 17,891 shares for € 85,132.33

As a reminder:

- the following resources appeared on the last half year statement on 30 June 2023 on the liquidity account:
 - 43,423 shares
 - € 382,720.54
 - Number of executions on buy side on semester: 631
 - Number of executions on sell side on semester: 505
 - Traded volume on buy side on semester: 59,726 shares for € 419,225.09
 - Traded volume on sell side on semester: 50,122 shares for € 385,042.61
- the following resources appeared on the liquidity account when the activity started:
 - 0 shares
 - € 600,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

About ACTICOR BIOTECH

Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), which is aiming to develop an innovative treatment for cardiovascular emergencies, including ischemic stroke.

The positive results of the phase 1b/2a study, ACTIMIS, confirmed the safety profile of glenzocimab and showed a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group of stroke patients. These results were confirmed by a post-hoc analysis of brain imaging at 0 and 24 hours using artificial intelligence (Brainomix, UK). This independent analysis confirmed the reduction in the number and volume of intracerebral lesions in patients treated with glenzocimab. The efficacy of glenzocimab is now being analyzed in an international Phase 2/3 study, ACTISAVE, with clinical results expected in Q2 2024.

In July 2022, Acticor Biotech was granted "PRIME" status by the European Medicines Agency (EMA) for glenzocimab in the treatment of stroke. This designation will allow the company to strengthen its interactions and obtain early dialogues with regulatory authorities.

Acticor Biotech is supported by a panel of European and international investors (Mediolanum farmaceutici, Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago, and the Armesa foundation). Acticor Biotech is listed on Euronext Growth Paris since November 2021 (ISIN: FR00140050J5 – ALACT). For more information, visit: www.acticor-biotech.com

Contacts

ACTICOR BIOTECH

Gilles AVENARD, MD

CEO and Founder

gilles.avenard@acticor-biotech.com

T. : +33 (0)6 76 23 38 13

Sophie BINAY, PhD

General Manager and CSO

Sophie.binay@acticor-biotech.com

T. : +33 (0)6 76 23 38 13

NewCap

Mathilde BOHIN

Investor Relations

acticor@newcap.eu

T. : +33 (0)1 44 71 94 95

NewCap

Arthur ROUILLÉ

Media Relations

acticor@newcap.eu

T. : +33 (0)1 44 71 00 15

	Buy side			Sell side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	340	39 590	173 764,12	227	17 891	85 132,33
03/07/2023	1	26	137,80	1	10	54,00
04/07/2023	-	-	-	3	240	1 296,00
05/07/2023	4	202	1 090,80	1	55	302,50
06/07/2023	2	238	1 309,00	5	672	3 736,32
07/07/2023	7	983	5 357,35	1	250	1 415,00
10/07/2023	2	250	1 350,00	3	38	209,00
11/07/2023	3	349	1 874,13	2	145	788,80
12/07/2023	3	63	333,90	8	818	4 441,74
13/07/2023	2	62	337,28	3	250	1 380,00
14/07/2023	5	230	1 260,40	1	18	100,44
17/07/2023	2	323	1 770,04	5	394	2 182,76
18/07/2023	2	370	2 023,90	7	106	585,12
19/07/2023	4	360	1 936,80	2	251	1 355,40
20/07/2023	4	154	831,60	2	150	819,00
21/07/2023	3	259	1 398,60	2	11	60,39
24/07/2023	1	170	921,40	5	184	1 010,16
25/07/2023	1	1	5,56	1	1	5,56
26/07/2023	3	175	962,50	1	1	5,54
27/07/2023	6	469	2 556,05	-	-	-
28/07/2023	1	246	1 328,40	1	100	544,00
31/07/2023	-	-	-	3	34	187,00
01/08/2023	2	255	1 377,00	1	1	5,50
02/08/2023	2	65	357,50	2	443	2 476,37
03/08/2023	-	-	-	2	5	28,00
07/08/2023	2	298	1 627,08	4	365	2 044,00
08/08/2023	8	1 102	5 741,42	1	1	5,42
09/08/2023	1	5	26,00	7	318	1 666,32
10/08/2023	3	441	2 275,56	1	1	5,22
11/08/2023	3	50	260,00	1	1	5,22
14/08/2023	1	3	15,60	3	112	593,60
15/08/2023	1	1	5,28	1	1	5,28
16/08/2023	1	1	5,28	3	36	190,80
17/08/2023	2	403	2 067,39	1	29	150,80
18/08/2023	1	1	5,12	3	407	2 136,75
21/08/2023	4	500	2 630,00	-	-	-
22/08/2023	2	251	1 305,20	1	1	5,16
23/08/2023	2	251	1 300,18	1	1	5,18
24/08/2023	1	1	5,18	1	1	5,18
25/08/2023	1	250	1 275,00	2	250	1 280,00
28/08/2023	-	-	-	3	250	1 300,00
29/08/2023	2	250	1 285,00	-	-	-
30/08/2023	2	250	1 300,00	2	500	2 635,00
31/08/2023	1	1	5,18	2	251	1 315,24

	Buy side			Sell side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	340	39 590	173 764,12	227	17 891	85 132,33
01/09/2023	2	250	1 425,00	6	1 389	8 195,10
04/09/2023	1	207	1 159,20	3	381	2 274,57
05/09/2023	2	43	240,80	-	-	-
06/09/2023	10	1 250	7 062,50	-	-	-
07/09/2023	3	257	1 444,34	1	1	5,70
08/09/2023	1	30	166,20	1	1	5,70
11/09/2023	4	330	1 824,90	1	1	5,70
12/09/2023	5	262	1 441,00	2	250	1 380,00
13/09/2023	7	585	3 176,55	3	125	692,50
14/09/2023	2	262	1 388,60	2	250	1 350,00
15/09/2023	-	-	-	6	874	4 955,58
18/09/2023	11	1 452	8 058,60	-	-	-
19/09/2023	3	486	2 600,10	-	-	-
20/09/2023	1	250	1 325,00	1	250	1 330,00
21/09/2023	1	78	405,60	-	-	-
22/09/2023	5	623	3 214,68	1	1	5,24
25/09/2023	5	700	3 570,00	-	-	-
26/09/2023	3	379	1 883,63	-	-	-
27/09/2023	2	251	1 229,90	1	1	4,99
28/09/2023	3	500	2 425,00	1	1	4,91
29/09/2023	1	150	721,50	3	30	145,50
02/10/2023	-	-	-	4	369	1 800,72
03/10/2023	3	272	1 330,08	3	360	1 774,80
04/10/2023	3	283	1 352,74	-	-	-
05/10/2023	17	2 501	10 979,39	-	-	-
06/10/2023	3	501	2 154,30	5	251	1 084,32
09/10/2023	-	-	-	7	367	1 633,15
10/10/2023	-	-	-	4	133	598,50
11/10/2023	2	500	2 275,00	1	250	1 172,50
12/10/2023	5	850	3 748,50	2	160	715,20
13/10/2023	2	44	191,84	1	1	4,38
16/10/2023	2	130	564,20	-	-	-
17/10/2023	4	715	3 003,00	1	1	4,31
18/10/2023	6	750	3 000,00	-	-	-
19/10/2023	3	401	1 579,94	-	-	-
20/10/2023	3	166	649,06	2	101	397,94
23/10/2023	3	783	3 038,04	7	410	1 607,20
24/10/2023	-	-	-	1	29	113,10
25/10/2023	5	251	953,80	1	1	3,88
26/10/2023	3	254	957,58	4	332	1 261,60
27/10/2023	2	150	570,00	2	21	81,06
30/10/2023	-	-	-	3	299	1 163,11
31/10/2023	3	501	1 923,84	1	1	3,88

	Buy side			Sell side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
Total	340	39 590	173 764,12	227	17 891	85 132,33
01/11/2023	2	197	728,90	1	1	3,75
02/11/2023	3	440	1 641,20	1	4	15,40
03/11/2023	2	61	225,70	1	1	3,73
06/11/2023	1	73	273,75	2	50	189,00
07/11/2023	2	327	1 232,79	1	250	950,00
08/11/2023	1	225	843,75	-	-	-
09/11/2023	1	1	3,79	4	251	953,80
10/11/2023	3	275	1 045,00	1	1	3,81
13/11/2023	1	150	568,50	1	245	931,00
14/11/2023	2	91	345,80	1	1	3,81
15/11/2023	3	545	2 071,00	1	237	905,34
16/11/2023	3	315	1 197,00	1	263	1 004,66
17/11/2023	-	-	-	2	490	1 935,50
20/11/2023	5	900	3 402,00	-	-	-
21/11/2023	-	-	-	1	1	3,80
22/11/2023	4	89	336,42	2	132	501,60
23/11/2023	3	12	45,36	2	119	452,20
24/11/2023	3	283	1 069,74	-	-	-
27/11/2023	3	500	1 870,00	-	-	-
28/11/2023	11	2 250	6 615,00	-	-	-
29/11/2023	4	595	1 719,55	-	-	-
30/11/2023	2	225	652,50	-	-	-
01/12/2023	1	250	725,00	-	-	-
05/12/2023	2	403	1 168,70	-	-	-
06/12/2023	2	247	716,30	-	-	-
07/12/2023	3	252	730,80	1	1	2,88
08/12/2023	5	599	1 737,10	-	-	-
11/12/2023	1	100	290,00	-	-	-
12/12/2023	1	250	725,00	-	-	-
13/12/2023	2	250	700,00	-	-	-
14/12/2023	4	200	570,00	1	9	26,37
15/12/2023	5	750	2 100,00	-	-	-
18/12/2023	1	100	280,00	3	250	715,00
19/12/2023	3	36	101,52	2	500	1 435,00
20/12/2023	-	-	-	1	1	2,88
21/12/2023	1	214	603,48	2	37	105,08
22/12/2023	5	751	2 095,29	5	464	1 308,48
27/12/2023	3	479	1 365,15	7	990	2 841,30
28/12/2023	2	250	710,00	1	1	2,93
29/12/2023	1	199	569,14	2	249	722,10